ANI Pharmaceuticals Inc Common Stock (ANIP) Receives $83.50 Consensus PT from Analysts

Shares of ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) have been given an average rating of “Hold” by the six research firms that are covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $78.00.

ANIP has been the topic of a number of recent research reports. ValuEngine cut ANI Pharmaceuticals Inc Common Stock from a “buy” rating to a “hold” rating in a report on Saturday, July 28th. BidaskClub raised ANI Pharmaceuticals Inc Common Stock from a “hold” rating to a “buy” rating in a report on Wednesday, June 13th. Zacks Investment Research cut ANI Pharmaceuticals Inc Common Stock from a “buy” rating to a “hold” rating in a report on Tuesday, July 10th. Canaccord Genuity set a $82.00 target price on ANI Pharmaceuticals Inc Common Stock and gave the stock a “buy” rating in a report on Tuesday, May 8th. Finally, Cantor Fitzgerald initiated coverage on ANI Pharmaceuticals Inc Common Stock in a report on Monday, June 11th. They issued a “buy” rating and a $85.00 target price on the stock.

ANI Pharmaceuticals Inc Common Stock stock traded up $0.33 during trading on Tuesday, reaching $57.04. The company had a trading volume of 70,223 shares, compared to its average volume of 130,344. ANI Pharmaceuticals Inc Common Stock has a 52 week low of $43.21 and a 52 week high of $74.70. The stock has a market cap of $668.95 million, a P/E ratio of 15.80 and a beta of 2.78. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.75 and a current ratio of 3.84.

ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) last announced its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $1.13 EPS for the quarter, missing the Zacks’ consensus estimate of $1.34 by ($0.21). ANI Pharmaceuticals Inc Common Stock had a return on equity of 27.76% and a net margin of 0.06%. The company had revenue of $47.27 million during the quarter, compared to the consensus estimate of $50.70 million. analysts predict that ANI Pharmaceuticals Inc Common Stock will post 4.49 EPS for the current year.

In other ANI Pharmaceuticals Inc Common Stock news, Director Tracy Marshbanks sold 38,236 shares of the stock in a transaction on Wednesday, May 16th. The stock was sold at an average price of $62.33, for a total value of $2,383,249.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 33.10% of the company’s stock.

A number of hedge funds have recently modified their holdings of ANIP. Mount Yale Investment Advisors LLC purchased a new position in shares of ANI Pharmaceuticals Inc Common Stock during the first quarter valued at about $102,000. Sei Investments Co. grew its position in shares of ANI Pharmaceuticals Inc Common Stock by 56.9% during the first quarter. Sei Investments Co. now owns 2,252 shares of the specialty pharmaceutical company’s stock valued at $131,000 after purchasing an additional 817 shares in the last quarter. Piedmont Investment Advisors LLC purchased a new position in shares of ANI Pharmaceuticals Inc Common Stock during the second quarter valued at about $140,000. Trexquant Investment LP purchased a new position in shares of ANI Pharmaceuticals Inc Common Stock during the first quarter valued at about $205,000. Finally, Millennium Management LLC purchased a new position in shares of ANI Pharmaceuticals Inc Common Stock during the fourth quarter valued at about $210,000. Institutional investors and hedge funds own 56.25% of the company’s stock.

ANI Pharmaceuticals Inc Common Stock Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.

Featured Story: Marijuana Stocks Investing Considerations

Receive News & Ratings for ANI Pharmaceuticals Inc Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply